Navitoclax

• Description :

  Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].

• Product Name Alternative :

  ABT-263

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Bcl-2 Family

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/navitoclax.html

• Purity :

  99.97

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=S(C1=CC(S(NC(C2=CC=C(N3CCN(CC4=C(CCC(C)(C4)C)C5=CC=C(Cl)C=C5)CC3)C=C2)=O)(=O)=O)=CC=C1N[C@H](CCN6CCOCC6)CSC7=CC=CC=C7)(C(F)(F)F)=O

• Molecular Formula :

  C47H55ClF3N5O6S3

• Molecular Weight :

  974.61

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Lock R1, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50 (6) :1181-1189.|[2]Wong M, et al. Navitoclax (ABT-263) reduces Bcl-x (L) -mediated chemoresistance in ovarian cancer models.Mol Cancer Ther. 2012 Apr;11 (4) :1026-1035.|[3]Chen J, et al. The Bcl-2/Bcl-X (L) /Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10 (12) :2340-9.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• Isoform :

  Bcl-2; Bcl-W; Bcl-xL

• CAS Number :

  [923564-51-6]